

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Applicant:

10 JUL 2006

Hermona SOREQ, et al

Serial No.: National Phase of PCT/IL2005/000028

Filed:                      Herewith

For: COMPOUNDS, PHARMACEUTICAL  
COMPOSITIONS AND THERAPEUTIC  
METHODS ...

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Attorney  
Docket: 30394

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Mozurk

Martin D. Moynihan  
Registration No. 40,338

Dated: July 10, 2006

PTO/SB/08a (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	National Phase of PCT/IL2005/000028
				Filing Date	Herewith
				First Named Inventor	Hermona SOREQ et al
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	30394
Sheet	1	30394	3		

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	5	PCT WO 2004/098669	11-18-2004	Cohen et al.		
	6	PCT WO 99/15211	01-1-1999	Borland et al.		
	7	EP 1025869	09-9-2000	Zimmermann		
	8	EP 1270594	02-2-2003	Greenfield et al.		
	9	PCT WO 03/054182	03-3-2003	Karatzas et al.		
Examiner Signature				Date Considered		

**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

10 JUL 2006

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	National Phase of PCT/IL2005/000028
				Filing Date	Herewith
				First Named Inventor	Hermona SOREQ et al
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	Of	3	Attorney Docket Number	30394
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	10	Redfield "Heart Failure - An Epidemic of Uncertain Proportions", The New England Journal of Medicine, 347(18): 1442-1444, 2002.			
	11	Douglas et al. "Mechanisms and Models in Heart Failure - A Combinatorial Approach", Circulation, 100: 999-1008, 1999.			
	12	Pilla et al. "Ventricular Constraint Using the Acorn Cadiac Support Device Reduces Myocardial Akinetic Area in An Ovine Model of Acute Infarction", Circulation, 106: 207-211, 2002.			
	13	Sutton et al. "Left Ventricular Remolding After Myocardial Infarction - Pathophysiology and Therapy", Circulation 101:2981-2988, 2000.			
	14	Gonzales et al. "The Neuropeptide Y Y1 Receptor Mediates NPV-Induced Inhibition of the Gonadotrope Axis Under Poor Metabolic Conditions", The FASEB Journal Online, 2003.			
	15	Leor et al. "Transplantation of Fetal Myocardial Tissue Into the Infarcted Myocardium of Rat - A Potential Method for Repair of Infarcted Myocardium", Circulation, 94(9): 332-336, 1996.			
	16	Atala et al. "Injectable Alginate Seeded With Chondrocytes as A Potential Treatment for Vesicoureteral Reflux", The Journal of Urology, 150, 745-747, 1993.			
	17	Aebischer et al. "Transplatation in Humans of Encapsulated Xenogeneic Cells Without Immunosuppression", Transplantation, 58(11): 1275-1277, 1994.			
	18	Mehta et al. "Functional Infarct Expansion, Left Ventricular Dilation and Isovolumic Relaxation Time After Coronary Occlusion: A Two-Dimensional Echocardiographic Study", Journal of the American Coll. Cardiology, 11(3): 630-636, 1988.			
	19	Suggs et al. "Preparation and Characterization of Poly (Propylene Fumarate-Co-Ethylene Glycol) Hydrogels", Journal of Biomater. Sci. Polymer Edn., 9(7): 653-666, 1998.			
	20	Rosenblatt et al. "Culturing Satellite Cells From Living Single Muscle Fiber Explants", In Vitro Cell. Dev. Biol. - Animal, 31: 773-779, 1995.			
	21	Schiller et al. "Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography", Journal of the American Society of Echocardiography, 2(5): 358-367, 1989.			
	22	Leor et al. "Cell Transplantation and Genetic Engineering: New Approaches to Cardiac Pathology", Expert Opinion in Biological Therapy, 3(7): 1023-1039, 2003.			
	23	Knight et al. "Nonsurgical Septal Reduction for Hypertrophic Obstructive Cardiomyopathy", Circulation, 95: 2075-2081, 1997.			
	24	Yau et al. "Beneficial Effect of Autologous Cell Transplantation on Infarcted Heart Function: Comparison Between Bone Marrow Stromal Cells and Heart Cells", Annual of Thoracic Surgeons, 75: 169-177, 2003.			
	25	Beltrami et al. "Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration", Cell, 114: 763-776, 2003.			
	26	Jugdutt "Ventricular Remodeling After Infarction and the Extracellular Collagen Matrix: When Is Enough Enough?", Circulation, 108: 1395-1403, 2003.			
Signature				Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Applicant's unique citation designation number (optional). <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	National Phase of PCT/IL2005/000028
				Filing Date	Herewith
				First Named Inventor	Hermona SOREQ et al
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	30394	3	Attorney Docket Number	30394
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	27	Jessup et al. "Heart Failure", The New England Journal of Medicine, 348: 2007-2018, 2003.			
	28	Madeddu et al. "Transplantation of Low Dose CD34+Kdr+ Cells Promotes Vascular and Muscular Regeneration in Ischemic Limbs", The FASEB Journal, 18(14): 1737-1739, 2004.			
	29	Perin et al. "Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure", Circulation, 107: 2294-2302, 2003.			
	30	Leor et al. "Bioengineered Cardiac Grafts: A New Approach to Repair the Infarcted Myocardium?", Circulation, 102(Suppl.III): III-56 - III-61, 2000.			
	31	Etzion et al. "Influence of Embryonic Cardiomyocyte Transplantation on the Progression of Heart Failure in A Rat Model of Extensive Myocardial Infarction", Journal of Molecular and Cellular Cardiology, 33: 1321-1330, 2001.			
	32	Babiak et al. "Coordinated Activation of VEGFR-1 and VEGFR-2 Is A Potent Arteriogenic Stimulus Leading to Enhancement of Regional Perfusion", Cardiovascular Research, 61: 789-795, 2004.			
	33	Khand et al. "Clinical Events Leading to the Progression of Heart Failure: Insights From A National Database of Hospital Discharges", European Heart Journal, 22: 153-164, 2001.			
	34	Couffinhal et al. "Mouse Model of Angiogenesis", American Journal of Pathology, 152(6): 1667-1679, 1998.			

Signature		Considered	
-----------	--	------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Applicant's unique citation designation number (optional). <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.